Search research articles
Contact Us
Filters
Showing results (191-200 of 215) with videos related to
Page
of 22
Sort By:
Nature Communications
|
March 21, 2020
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
Anniina Färkkilä, Doga C Gulhan, Julia Casado, et al.
JAMA Oncology
|
June 14, 2019
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
Panagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, et al.
Cancer Research
|
October 15, 2024
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors
Louise Cadzow, Jehrod Brenneman, Erica Tobin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2017
Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
Douglass W Tucker, Christopher R Getchell, Eric T McCarthy, et al.
Nature Communications
|
May 20, 2020
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
Anniina Färkkilä, Doga C Gulhan, Julia Casado, et al.
Gynecologic Oncology
|
May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer
Elizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 10, 2012
Ovarian cancer, version 3.2012
Robert J Morgan, Ronald D Alvarez, Deborah K Armstrong, et al.
The Lancet. Oncology
|
June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
The New England Journal of Medicine
|
October 9, 2016
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 22, 2013
Ovarian cancer, version 2.2013
Robert J Morgan, Ronald D Alvarez, Deborah K Armstrong, et al.
Page
of 22
Search research articles
Search
Showing results (191-200 of 215) with videos related to
Sort By:
Page
of 22
Nature Communications
|
March 21, 2020
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
Anniina Färkkilä, Doga C Gulhan, Julia Casado, et al.
JAMA Oncology
|
June 14, 2019
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
Panagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, et al.
Cancer Research
|
October 15, 2024
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors
Louise Cadzow, Jehrod Brenneman, Erica Tobin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2017
Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
Douglass W Tucker, Christopher R Getchell, Eric T McCarthy, et al.
Nature Communications
|
May 20, 2020
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
Anniina Färkkilä, Doga C Gulhan, Julia Casado, et al.
Gynecologic Oncology
|
May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer
Elizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 10, 2012
Ovarian cancer, version 3.2012
Robert J Morgan, Ronald D Alvarez, Deborah K Armstrong, et al.
The Lancet. Oncology
|
June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
The New England Journal of Medicine
|
October 9, 2016
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 22, 2013
Ovarian cancer, version 2.2013
Robert J Morgan, Ronald D Alvarez, Deborah K Armstrong, et al.
Page
of 22